PT  - JOURNAL ARTICLE
ED  - ,
TI  - ▼Agomelatine for major depressive episodes
AID  - 10.1136/dtb.2010.08.0043
DP  - 2010 Aug 01
TA  - Drug and Therapeutics Bulletin
PG  - 93--96
VI  - 48
IP  - 8
4099  - http://dtb.bmj.com/content/48/8/93.short
4100  - http://dtb.bmj.com/content/48/8/93.full
SO  - Drug Ther Bull2010 Aug 01; 48
AB  - Relevant BNF section: BNF 4.3.4 ▼Agomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug acts simultaneously as a melatonin receptor agonist and a serotonin receptor antagonist and claims that it is a “major therapeutic advance in management of depression through the restoration of circadian rhythms”.1 Here we consider whether agomelatine offers significant advantage for patients with major depressive episodes.